(Total Views: 386)
Posted On: 11/08/2021 2:50:09 PM
Post# of 61
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s presentation will begin at 3:30 p.m. ET on Nov. 17. Case will provide an overview of the company, including a look at how Anpac Bio is democratizing early cancer screening and detection; he will also be available for one-on-one meetings with qualified investors. The company noted that existing early cancer screening and detection methods offer limited clinical utility and show average to nonexistent performance. The company provides its own novel and comprehensive platform featuring Cancer Differentiation Analysis (“CDA”) technology for cancer screening and detection. The technology measures biophysical properties designed to identify cancer and precancerous diseases as early as possible while also determining personalized cancer risk.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s presentation will begin at 3:30 p.m. ET on Nov. 17. Case will provide an overview of the company, including a look at how Anpac Bio is democratizing early cancer screening and detection; he will also be available for one-on-one meetings with qualified investors. The company noted that existing early cancer screening and detection methods offer limited clinical utility and show average to nonexistent performance. The company provides its own novel and comprehensive platform featuring Cancer Differentiation Analysis (“CDA”) technology for cancer screening and detection. The technology measures biophysical properties designed to identify cancer and precancerous diseases as early as possible while also determining personalized cancer risk.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
